SMAD4 and cancer: There are also several systematic reviews that studied the clinicopathological significance of SMAD4 loss in various cancers [3, 18–20], which had revealed that loss of SMAD4 was indeed associated with poorer survival and hence, is a negative prognostic indicator in patients.